Increased levels of urinary adenosine deaminase binding protein in children treated with cisplatin or methotrexate.
Levels of adenosine deaminase binding protein (ABP), a renal tubular cell antigen, were determined by enzyme immunoassay in urine specimens from seven children with solid tumors who were receiving the recognized nephrotoxins cisplatin or methotrexate. ABP excretion was uniformly increased within the first 3 days after administration of either drug. Elevated ABP levels were usually accompanied by increased excretion of the urinary enzymes N-acetyl-beta-D-glucosaminidase and alanine aminopeptidase. In alkaline urine specimens associated with methotrexate therapy, ABP levels were increased whereas enzyme activities appeared to be unstable. Hence, immunochemical measurement of urinary ABP levels may be adjunctively useful for clinical studies of renal tubular damage.
D000118:Acetylglucosaminidase / Q000652:urine; D000626:Aminopeptidases / Q000652:urine; D018826:CD13 Antigens; D002352:Carrier Proteins / Q000652:urine*; D002648:Child; D002945:Cisplatin / Q000627:therapeutic use*; D018819:Dipeptidyl Peptidase 4; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use*; D013997:Time Factors
D002352:Carrier Proteins; D000118:Acetylglucosaminidase; D000626:Aminopeptidases; D018826:CD13 Antigens; D018819:Dipeptidyl Peptidase 4; D002945:Cisplatin; D008727:Methotrexate